Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Abviax's Obefazimod shows strong potential in ulcerative colitis treatment. Upcoming phase 3 trial data in Q3 2025 is a key ...

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is often perceived as a condition ...

Major and minor relapses are relatively common in GCA and primarily occur within the first 2 years of diagnosis.